Safety learning from drugs of the same class: Room for improvement

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 5, 2012, Pages 872-880

  Stefansdottir, G ^a,b   Knol, M J ^a,b   Arnardottir, A H ^c   Van Der Elst, M E ^d   Grobbee, D E ^a   Leufkens, H G M ^b,d   De Bruin, M L ^b,d  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d MEDICINES EVALUATION BOARD   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANIDULAFUNGIN; BOSENTAN; CASPOFUNGIN; CLADRIBINE; CLOFARIBINE; EFAVIRENZ; ETANERCEPT; HUMAN GROWTH HORMONE; HUMAN INSULIN; INDINAVIR; INFLIXIMAB; INSULIN ASPART; INSULIN LISPRO; LENALIDOMIDE; NATEGLINIDE; NEVIRAPINE; OXIDOREDUCTASE INHIBITOR; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RECOMBINANT SOMATOMEDIN C; REPAGLINIDE; RITUXIMAB; SAQUINAVIR; SILDENAFIL; SITAGLIPTIN; SITAXSENTAN; TADALAFIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILDAGLIPTIN;

ANEMIA; ARTHRITIS; ARTICLE; ASPERGILLOSIS; BLOOD DISEASE; BONE DISEASE; BONE MARROW DISEASE; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CANDIDIASIS; CARDIOVASCULAR DISEASE; CEREBELLUM DISEASE; COLITIS; COLORECTAL CANCER; CROHN DISEASE; DIABETES MELLITUS; DISORDERS OF CARBOHYDRATE METABOLISM; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ERECTILE DYSFUNCTION; FOLLOW UP; GASTROINTESTINAL DISEASE; GRAFT REJECTION; HAIRY CELL LEUKEMIA; HEAD AND NECK CANCER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; KIDNEY DISEASE; LARON SYNDROME; LEARNING; LEUKEMIA; LIVER DISEASE; LUNG DISEASE; LYMPHOMA; MENTAL DISEASE; MULTIPLE MYELOMA; NEOPLASM; OSTEOPOROSIS; OVULATION INDUCTION; PANCREATITIS; PHOSPHATE METABOLISM; POSTMARKETING SURVEILLANCE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PSORIASIS; PULMONARY HYPERTENSION; RETINA DISEASE; RISK MANAGEMENT; SIDE EFFECT; SURVIVAL TIME; TISSUE GROWTH; TOTAL QUALITY MANAGEMENT; TUMOR GROWTH; WEIGHT CHANGE;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG TOXICITY; HUMANS; KAPLAN-MEIER ESTIMATE; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 84859947715     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.319     Document Type: Article

References (27)

1. Lazarou, J., Pomeranz, B.H. & Corey, P.N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279, 1200-1205 (1998).
2. Lacoste-Roussillon, C., Pouyanne, P., Haramburu, F., Miremont, G. & Bégaud, B. Incidence of serious adverse drug reactions in general practice: a prospective study. Clin. Pharmacol. Ther. 69, 458-462 (2001).
3. Bates, D.W. et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA 274, 29-34 (1995).
4. Berlin, J.A., Glasser, S.C. & Ellenberg, S.S. Adverse event detection in drug development: recommendations and obligations beyond phase 3. Am. J. Public Health 98, 1366-1371 (2008).
5. Stricker, B.H. & Psaty, B.M. Detection, verification, and quantification of adverse drug reactions. BMJ 329, 44-47 (2004).
6. Farahani, P., Levine, M., Gaebel, K. & Thabane, L. Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis. Can. J. Clin. Pharmacol. 12, e254-e263 (2005).
7. Roozenbeek, B. et al.; IMPACT Study Group. Baseline characteristics and statistical power in randomized controlled trials: selection, prognostic targeting, or covariate adjustment? Crit. Care Med. 37, 2683-2690 (2009).
8. Tobin, J.J. & Walsh, G. Medicinal Product Regulatory Affairs. Weinheim, Germany: Wiley-Blackwell, 2008.
9. European Commission. Rules Governing Medicinal Products in the European Union: Guidelines on Pharmacovigilance for Medicinal Products for Human Use, Vol. 9A (2008). 〈http://ec.europa.eu/health/files/eudralex/vol-9/pdf/vol9a- 09-2008-en.pdf〉.
10. Giezen, T.J. et al. Evaluation of post-authorization safety studies in the first cohort of EU Risk Management Plans at time of regulatory approval. Drug Saf. 32, 1175-1187 (2009).
11. Frau, S., Font Pous, M., Luppino, M.R. & Conforti, A. Risk Management Plans: are they a tool for improving drug safety? Eur. J. Clin. Pharmacol. 66, 785-790 (2010).
12. US Food and Drug Administration. Executive Summary. Managing the Risks from Medicinal Product Use - Creating a Risk Management Framework. (1999).
13. Lasser, K.E., Allen, P.D., Woolhandler, S.J., Himmelstein, D.U., Wolfe, S.M. & Bor, D.H. Timing of new black box warnings and withdrawals for prescription medications. JAMA 287, 2215-2220 (2002).
14. Edwards, I.R., Lindquist, M., Wiholm, B.E. & Napke, E. Quality criteria for early signals of possible adverse drug reactions. Lancet 336, 156-158 (1990).
15. Abernethy, D.R., Woodcock, J. & Lesko, L.J. Pharmacological mechanism-based drug safety assessment and prediction. Clin. Pharmacol. Ther. 89, 793-797 (2011).
16. Arnardottir, A.H., Haaijer-Ruskamp, F.M., Straus, S.M., de Graeff, P.A. & Mol, P.G. Effect of safety issues with HIV drugs on the approval process of other drugs in the same class: an analysis of European Public Assessment Reports. Drug Saf. 34, 1101-1114 (2011).
17. Kim, J.H. & Scialli, A.R. Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol. Sci. 122, 1-6 (2011).
18. Giezen, T.J., Mantel-Teeuwisse, A.K., Straus, S.M., Schellekens, H., Leufkens, H.G. & Egberts, A.C. Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA 300, 1887-1896 (2008).
19. Haffner, M.E., Whitley, J. & Moses, M. Two decades of orphan product development. Nat. Rev. Drug Discov. 1, 821-825 (2002).
20. Giezen, T.J., Straus, S.M. & Mantel-Teeuwisse, A.K. Pharmacovigilance of biosimilars from a regulatory point of view: Is there a need for a specific approach? Int. J. Risk Safety. Med. 53-58 (2009).
21. Baumann, A. Early development of therapeutic biologics-pharmacokinetics. Curr. Drug Metab. 7, 15-21 (2006).
22. European Medicines Agency. European Public Assessment Reports (EPARs). 〈http://www.ema.europa.eu/ema/index.jsp?curl=/pages/medicines/landing/ epar-search.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01 ac058001d125&jsenabled=true〉 (2010).
23. European Commission. European Commission Community Register, 〈http://ec.europa.eu/health/documents/community-register/html/index-en. htm〉(2010).
24. Rawlins, M. & Thompson, W. Mechanisms of adverse drug reactions. In: Davies D, ed. Textbook of Adverse Drug Reactions (Oxford University Press, New York, 1991).
25. Pichler, W.J. Adverse side-effects to biological agents. Allergy 61, 912-920 (2006).
26. Giezen, T.J. et al. Adverse Drug Reactions of Biologicals: How Spontaneously Reported Adverse Drug Reactions Fit a Newly Proposed Classification System, Chapter 3.2 (Utrecht University, Utrecht, The Netherlands, 2010).
27. MedDRA MSSO. Medical Dictionary for Regulatory Activities 〈http://www.meddramsso.com/index.asp〉. Accessed 24 November 2010.